patent.fyi
Applications  /  US 2026/0355198
United States Patent Application Publication

US 2026/0355198 A1

Published
Nov 12, 2026
Filed
Jul 17, 2026
Earliest date on the face
Dec 18, 2020
Classification
A61K 31/506
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Deliver by subcutaneous injection

What ifWhat if treatment is delivered by subcutaneous injection?
Claim language“orally administering”

A small-volume syringe deposits a sterile C-type natriuretic peptide analog solution into subcutaneous tissue. The peptide enters circulation and activates natriuretic peptide receptor B, which counteracts downstream FGFR3 signaling in growth-plate cartilage.

1.1Set dose by drug exposure

What ifWhat if the oral dose is set as an absolute mass from measured drug exposure?
Claim language“about 0.25 mg/kg”

In a dose-finding protocol, timed plasma samples and a pharmacokinetic model estimate the area under the concentration–time curve. The protocol selects a fixed tablet strength against a prespecified exposure range and repeats sampling after a dose adjustment.

1.1Test a different oral compound

What ifWhat if the oral active ingredient is an antihistamine studied for its effects on growth-plate cartilage?
Claim language“infigratinib, or a pharmaceutically acceptable salt thereof”

A tablet delivers a piperazine antihistamine selected for its effects on cartilage cells in experimental models of achondroplasia. A controlled dose-finding study measures drug exposure and uses serial height measurements to assess growth velocity.

1.1Use a weekly injection

What ifWhat if treatment is administered once weekly?
Claim language“per day”

A subcutaneous injection delivers a peptide analog attached to a polymer carrier through a cleavable linker. The linker releases active peptide over several days, sustaining natriuretic peptide receptor B stimulation between weekly injections.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Home administration with daily dose pouches

A pharmacy packages each prescribed daily oral dose of infigratinib minitablets in a sealed pouch. Each pouch carries the administration date, tablet strength, and tablet count. The caregiver opens the pouch for the scheduled date, administers its contents, and records the administration in a home medication log.

Component substitution

Hard capsules filled with oral granules

A hard hydroxypropyl methylcellulose capsule containing infigratinib monophosphate granules replaces the compressed minitablet. The granules contain microcrystalline cellulose as a diluent and povidone as a binder. A capsule filler meters the granules by weight, and the labeled strength expresses the infigratinib content per capsule. Batch testing measures content uniformity and dissolution.

Parameter or scale variation

Seven day and twenty eight day packs

A calendar blister pack contains either one row of 7 daily cavities or four rows of 7 daily cavities. Each cavity contains the full prescribed oral dose for one day, and the cavity depth accommodates the tablet count specified for the pack. Printed dates map each cavity to a scheduled administration.

Combination with existing systems

Barcode verification during clinic administration

An electronic medication administration record links the oral infigratinib order to a barcode on each unit-dose pouch. Clinic staff scan the patient identifier and the pouch before administration. The system checks the patient, drug, strength, and scheduled dose against the active order and records the administration time after staff confirmation.

Automated or data-driven variant

Weight based dose calculation and verification

Prescribing software imports the latest verified body weight in kilograms and multiplies it by the prescribed daily factor of about 0.25 mg/kg. The software compares the calculated amount with the doses deliverable using whole minitablets of the stocked strengths. It displays the tablet count and the difference from the calculated amount for prescriber confirmation before dispensing.

Electronic logging of blister cavity openings

A printed conductive trace crosses the backing of each daily blister cavity and connects to a detachable reader. Opening a cavity breaks its trace, and the reader stores the cavity number and timestamp. A caregiver interface displays the opening time alongside a separate field for recording administration.

Specific version of a part

Use monophosphate minitablets

Compressed minitablets contain infigratinib monophosphate, microcrystalline cellulose as a filler, and a disintegrant. The tablet count is based on the amount of infigratinib active moiety per unit and the patient's measured body mass, targeting about 0.25 mg/kg per day.

Measure an oral suspension

An oral suspension contains infigratinib monophosphate at a defined concentration expressed as milligrams of infigratinib active moiety per milliliter. The caregiver shakes the bottle and uses a graduated oral syringe to measure the volume corresponding to about 0.25 mg/kg once daily.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2011/0135723 A1
Published
Jun 9, 2011
Filed
Jun 17, 2010
Class
A61K 31/195
Document BUS 2012/0251590 A1
Published
Oct 4, 2012
Filed
Mar 30, 2012
Class
A61K 9/00
Claim 1
Document A
Document B
1.1orally administering to the human subject about 0.25 mg/kg of infigratinib, or a pharmaceutically acceptable salt thereof, per day.
In yet another embodiment the present invention provides a method of treating a condition or disorder in a subject that is responsive to pregabalin the method comprising administering subject once daily pharmaceutical composition comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and one or more water insoluble component. The method includes orally administering to the subject once per day the pharmaceutical composition described above.
A · US 2011/0135723 A1 · ¶ 52
It is a further object of the present invention to provide oral dosage forms of hydrocodone and acetaminophen, or a pharmaceutically acceptable salt thereof, which are administrable on a twice-a-day basis and which provide effective treatment of pain in mammals, and in particular, humans.
B · US 2012/0251590 A1 · ¶ 24

An empty cell means only that no passage was reproduced there.

Statements in these documents
Conventional extended release (ER) compositions are problematic for dosing because pregabalin is not absorbed uniformly in the gastrointestinal (GI) tract.
A · US 2011/0135723 A1 · ¶ 5
Extending the period of time during which pregabalin is released in the stomach effectively widens the absorption window associated with IR dosing, thereby permitting once daily dosing.
A · US 2011/0135723 A1 · ¶ 8
Combination products providing delivery of relatively soluble drugs such as opioid analgesics and relatively insoluble drugs such as certain nonopioid analgesics are more difficult to prepare, however the preparation of some dosage forms has been reported.
B · US 2012/0251590 A1 · ¶ 3
Finally, the dosage forms did not release 90% of the analgesic agents within the time period reported for the dissolution profile, resulting in high amounts of residual drug in the formulations.
B · US 2012/0251590 A1 · ¶ 5
Cite aspatent.fyi, US 2026/0355198 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355198/, SHA-256 1af771409caefb8b68274bfba4f5c16d292ed30bec214a266485de5c5c82df58
First published
Permanent addresshttps://patent.fyi/US20260355198/
Content fingerprint (SHA-256)1af771409caefb8b68274bfba4f5c16d292ed30bec214a266485de5c5c82df58
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi